Hypoglycemic effects of exopolysaccharides produced by mycelial cultures of two different mushrooms Tremella fuciformis and Phellinus baumii in ob/ob mice.
The anti-diabetic activities of the exopolysaccharides (EPS) produced by submerged mycelial culture of two different mushrooms, Tremella fuciformis and Phellinus baumii, in ob/ob mice were investigated. All the animals were randomly divided into three groups with seven animals in each group: The control group received 0.9% NaCl solution; the diabetic groups were treated with EPS from T. fuciformis (Tf EPS) and P. baumii (Pb EPS) at the level of 200 mg/kg body weight using an oral zoned daily for 52 days. The plasma glucose levels in the EPS-fed mice were substantially reduced by about 52% (Tf EPS) and 32% (Pb EPS), respectively, as compared to control mice. The results of oral glucose tolerance test (OGTT) revealed that both EPS-fed groups significantly increased the glucose disposal after 52 days of EPS treatments. Furthermore, higher food efficiency ratios and reduced blood triglyceride levels were observed in the EPS-treated groups. Because peroxisome proliferator-activated receptor gamma (PPAR-gamma) is indeed a key regulator of insulin action, we investigated the expression pattern of adipose tissue PPAR-gamma messenger RNA (mRNA) and plasma levels of PPAR-gamma. It was revealed that PPAR-gamma was significantly activated in response to EPS treatments. The results suggested that both EPS exhibited considerable hypoglycemic effect and improved insulin sensitivity possibly through regulating PPAR-gamma-mediated lipid metabolism. Our results indicated that two mushroom-derived EPS might be developed as potential oral hypoglycemic agents or functional foods for the management of non-insulin-dependent diabetes mellitus.
Cho
Eun Jae
EJ
Department of Biotechnology, Daegu University, Kyungsan, Kyungbuk 712-714, Republic of Korea.
Hwang
Hye Jin
HJ
Kim
Sang Woo
SW
Oh
Jung Young
JY
Baek
Yu Mi
YM
Choi
Jang Won
JW
Bae
Song Hwan
SH
Yun
Jong Won
JW
D000818:Animals; D001487:Basidiomycota / Q000502:physiology*; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000235:genetics; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D025282:Mycelium / Q000502:physiology; D011134:Polysaccharides / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D011134:Polysaccharides